Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2020; Elsevier BV; Volume: 31; Issue: 9 Linguagem: Inglês
10.1016/j.annonc.2020.06.011
ISSN1569-8041
AutoresChris Parker, Elena Castro, Karim Fizazi, Axel Heidenreich, Piet Ost, Giuseppe Procopio, Bertrand Tombal, Silke Gillessen,
Tópico(s)Bladder and Urothelial Cancer Treatments
ResumoSubclinical prostate cancer is common in men >50 years. Population-based screening of men aged between 55 and 69 years, using prostate-specific antigen (PSA) testing, has been evaluated.1 After a median follow-up of 16 years, the European screening trial demonstrated a 25% relative reduction in prostate cancer mortality. However, 570 men needed to be invited for screening and 18 patients needed to be treated to prevent one death from prostate cancer, and there was no effect on overall survival (OS).
Referência(s)